Clinical Trials Logo

Age-Related Macular Degeneration clinical trials

View clinical trials related to Age-Related Macular Degeneration.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06391411 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly, characterized by multifactorial etiology. Recent evidence suggests a potential involvement of the gut-retina axis in AMD pathogenesis, prompting exploration into novel therapeutic strategies. The investigators assessed the effects of a micronutrient mix containing lutein, zeaxanthin, and saffron, recognized for their anti-inflammatory properties, on ophthalmological and microbial parameters in neovascular AMD (nAMD) patients. Thirty nAMD subjects were randomized to receive daily micronutrient supplementation along with anti-VEGF therapy or anti-VEGF treatment alone for 6 months. Ophthalmological assessments, anthropometric and biochemical measurements and stool samples were obtained pre- and post-treatment. Gut microbiota (GM) characterization was performed through 16S rRNA sequencing while short (SCFAs), medium (MCFAs) and long (LCFAs) chain fatty acids were analyzed with a gas chromatography-mass spectrometry protocol. nAMD patients exhibited reduced GM alpha diversity, altered taxonomic abundances and decreased total SCFA amount, coupled with elevated proinflammatory octanoic and nonanoic acids. Micronutrient supplementation led to improved visual acuity in comparison to the control group, along with the reduction in the total amount of MCFAs, metabolites exerting detrimental ocular effects. This study reveals compositional and functional imbalances in the GM of nAMD patients compared to healthy controls. Furthermore micronutrient supplementation demonstrated a potential to restore the gut-retina axis, suggesting its therapeutic efficacy in improving ocular outcomes in nAMD patients. These findings underscore the intricate interplay between the GM and ocular health, offering insights into innovative interventions for AMD management

NCT ID: NCT05963646 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

OMEGA
Start date: March 16, 2021
Phase:
Study type: Observational

This study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD). The study evaluates microperimetry (fundus-controlled perimetry) and optical coherence tomography imaging for assessing changes in retinal sensitivity and anatomy over time.

NCT ID: NCT05763940 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

Start date: May 25, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine increases in the Omega Index test indicating optimal Omega-3s particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels for overall systemic benefits including healthy cardiovascular health and cholesterol levels as shown in the OmegaIndex (OmegaQuant) research.

NCT ID: NCT05698316 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression

INTERCEPT-AMD
Start date: May 4, 2023
Phase:
Study type: Observational

This is a multicentre retrospective and prospective cohort study with the goal to develop a well-characterised multimodal image database of eyes with intermediate AMD with and without early atrophy. The main objectives are: 1. Develop a collaborative well-characterised database on intermediate AMD with or without early atrophy. 2. Grading of these images to explore imaging markers of progression. 3. Develop predictive models as a secondary analysis of our dataset. This study will recruit around 1.000 eyes in 6 months. All consenting patients who have had at least 3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria will be included in the study for retrospective data collection. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.

NCT ID: NCT05690880 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

ForeseeHome NRich Registry

Start date: December 15, 2022
Phase:
Study type: Observational [Patient Registry]

This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during routine care with Spectral Domain Optical Coherence Tomography (SD-OCT) and to validate the predictive value of a non-NV-AMD FSH alerts.

NCT ID: NCT05667441 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Adherence to Lifestyle Changes for Age-related Macular Degeneration

AMD-Life
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The AMD-Life study investigates which strategies (personalized risk-profiling including genetic testing and/or coaching) motivate AMD patients to change their lifestyle.

NCT ID: NCT05536297 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start date: September 26, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

NCT ID: NCT05391074 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Oral Postbiotics in Patients With Macular Atrophy

REVERS-GA
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

A pilot study to evaluate the safety and efficacy of oral therapy with Postbiotics in patients with geographic atrophy secondary to age-related macular degeneration, myopia, or angioid streaks.

NCT ID: NCT05380492 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Start date: November 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

NCT ID: NCT05265624 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

The Moran AMD Genetic Testing Assessment Study

MAGENTA
Start date: August 3, 2022
Phase: Phase 2
Study type: Interventional

The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.